BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17413003)

  • 1. Cancer immunologists and cancer biologists: why we didn't talk then but need to now.
    Prendergast GC; Jaffee EM
    Cancer Res; 2007 Apr; 67(8):3500-4. PubMed ID: 17413003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; CalabrĂ² L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
    Bhutia SK; Mallick SK; Maiti TK
    Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-driven evolution of immunosuppressive networks during malignant progression.
    Kim R; Emi M; Tanabe K; Arihiro K
    Cancer Res; 2006 Jun; 66(11):5527-36. PubMed ID: 16740684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dormant tumor cells as a therapeutic target?
    Quesnel B
    Cancer Lett; 2008 Aug; 267(1):10-7. PubMed ID: 18384938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation: gearing the journey to cancer.
    Kundu JK; Surh YJ
    Mutat Res; 2008; 659(1-2):15-30. PubMed ID: 18485806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cell-based cancer immunotherapy.
    Stagg J; Smyth MJ
    Drug News Perspect; 2007 Apr; 20(3):155-63. PubMed ID: 17520092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
    Whiteside TL
    Semin Cancer Biol; 2006 Feb; 16(1):3-15. PubMed ID: 16153857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of tumor-associated macrophages.
    Yuan A; Chen JJ; Yang PC
    Adv Clin Chem; 2008; 45():199-223. PubMed ID: 18429498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-evolution of tumor cells and their microenvironment.
    Polyak K; Haviv I; Campbell IG
    Trends Genet; 2009 Jan; 25(1):30-8. PubMed ID: 19054589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host response to colorectal cancer.
    Salama P; Platell C
    ANZ J Surg; 2008 Sep; 78(9):745-53. PubMed ID: 18844901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-host interactions: implications for developing anti-cancer therapies.
    Gadea BB; Joyce JA
    Expert Rev Mol Med; 2006 Dec; 8(30):1-32. PubMed ID: 17156575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From single disseminated tumor cells to metastasis insights from molecular genetic analyses of single cells].
    Klein CA
    Verh Dtsch Ges Pathol; 2003; 87():158-64. PubMed ID: 16888908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.